List view / Grid view
28 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced that it has signed a cooperative sales agreement with The Chemo-Sero-Therapeutic Research Institute on August 22 for its recombinant adsorbed hepatitis B vaccine (yeast-derived), Bimmugen®...
28 August 2014 | By GlaxoSmithKline
Unprecedented international consortium assembled to accelerate collaborative multi-site trials of candidate Ebola vaccine...
28 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to the company’s investigational Clostridium difficile vaccine candidate (PF-06425090). Currently in Phase 2 clinical development, the vaccine candidate is designed to prevent C...
28 August 2014 | By Amgen
...in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.
27 August 2014 | By Pfizer
Pfizer Inc. and Merck & Co. Inc. through a subsidiary, announced that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s crizotinib (XALKORI®) with Merck’s investigational anti-PD-1 antibody pembrolizumab...
27 August 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced that the European Commission has approved Daklinza (daclatasvir), a potent, pan-genotypic NS5A replication complex inhibitor (in vitro), for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults...
27 August 2014 | By Novo Nordisk
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech...
27 August 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the once-daily use of Promacta® (eltrombopag) in patients with severe aplastic anaemia who have had an insufficient response to immunosuppressive therapy...
26 August 2014 | By kdm communications
With clinical laboratories increasingly turning to high throughput LC-MSMS analysis, laboratory automation specialist Tecan and RECIPE Chemicals and Instruments GmbH have announced a co-marketing agreement for automation of LC-MSMS IVD kits...
26 August 2014 | By Roche
Roche and InterMune, Inc. announced they have entered into a definitive merger agreement for Roche to fully acquire InterMune at a price of US$ 74.00 per share in an all-cash transaction...
26 August 2014 | By Actavis
Actavis plc confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr...
26 August 2014 | By GlaxoSmithKline
ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection...
26 August 2014 | By Biogen Idec
Biogen Idec announced the appointment of Adriana Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014...
26 August 2014 | By AstraZeneca
AstraZeneca announced that it has entered into a collaboration with gene sequencing company, Illumina, Inc., to develop its next generation sequencing platform for companion diagnostic tests applicable across AstraZeneca’s oncology portfolio...
26 August 2014 | By Abbott
Abbott announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer...
